Biogen reports mixed Alzheimer’s trial results as industry sees new startup launches
read at Endpoints ↗Neutral
Biogen released data from its Alzheimer’s program that showed mixed outcomes, indicating some signals but also setbacks.
The weekly newsletter also highlighted the launch of two new biotech startups entering the market, though details were limited.
The edition noted ongoing Canadian wildfires affecting the US Northeast, reminding readers of broader environmental challenges.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Biogen’s mixed Alzheimer’s data; Two new startups launch; and more”
read at Endpoints ↗85 words · retrieved Jul 18
comments(0)
5-min edit window · permanent after that